CONTACT: Geoff Greenwood,
FOR IMMEDIATE RELEASE,
March 10, 2011
Miller, Dozens of State AGs Reach Landmark
$68.5 Million Astrazeneca Pharmacueticals Settlement
(DES MOINES, Iowa) In the largest ever multi-state consumer protection-based pharmaceutical settlement Attorney General Tom Miller announced today that he, along with 37 other attorneys general, reached a record $68.5 million dollar settlement with London-based AstraZeneca Pharmaceuticals LP arising from alleged improper marketing of the antipsychotic drug Seroquel. Miller said $1.17 million of the settlement will go to Iowa’s Consumer Education Litigation Fund.
The lawsuit, filed today in Polk County District Court along with the settlement agreement, alleges that AstraZeneca engaged in unfair and deceptive practices when it marketed Seroquel for unapproved or off-label uses, failed to adequately disclose the drug’s potential side effects to health care providers, and withheld negative information contained in scientific studies concerning the safety and efficacy of Seroquel.
“We had real concerns about how AstraZeneca was promoting Seroquel to doctors and patients here in Iowa and across the country, particularly for uses that the FDA did not authorize,” Miller said. “In many cases, patients experienced very serious side effects, including weight gain, diabetes and heart problems.”
Following a three-year investigation, AstraZeneca agreed to change how it markets Seroquel and to cease promoting Seroquel in a false, misleading or deceptive manner, including for “off-label” uses, which are not approved by the U.S. Food and Drug Administration. In addition to the $68.5 million payment, the terms of the settlement include injunctive provisions which address specific concerns identified in the investigation. Along with other prohibitions and requirements, the agreement specifically requires AstraZeneca to:
- Publicly post its payments to physicians on a website;
- Have policies in place to ensure that financial incentives are not given to marketing and sales personnel for off-label marketing;
- Have policies in place to ensure that AstraZeneca sales personnel do not promote to health care providers who are unlikely to prescribe Seroquel for an FDA-approved use; and
- Cite to Seroquel’s FDA-approved uses when referencing selected symptoms, rather than promoting Seroquel by highlighting symptoms only.
Although a physician is allowed to prescribe drugs for off-label uses, law prohibits pharmaceutical manufacturers from marketing their products for off-label uses. As alleged, AstraZeneca unlawfully marketed Seroquel for a number of off-label uses, including for use in pediatric and geriatric populations, specifically in nursing homes for Alzheimer’s Disease and Dementia, as well as for anxiety, depression, sleep disorders, and post traumatic stress disorder. AstraZeneca promoted Seroquel for such uses, even though Seroquel was not, at the time it was marketed, approved for the treatment of these conditions and AstraZeneca had not established that Seroquel was safe and effective for these uses.
Atypical antipsychotics, including Seroquel, can produce dangerous side effects, including weight gain, hyperglycemia, diabetes, cardiovascular complications, an increased risk of mortality in elderly patients with dementia and other severe conditions.
Attorneys general from Florida and Illinois led the investigation into AstraZeneca’s marketing and promotional practices. Attorneys general of Iowa, the District of Columbia, and the following states also participated in the settlement: Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, West Virginia and Wisconsin.
# # #